Literature DB >> 27155568

A specific, transmembrane interface regulates fibroblast activation protein (FAP) homodimerization, trafficking and exopeptidase activity.

Benjamaporn Wonganu1, Bryan W Berger2.   

Abstract

Fibroblast activation protein (FAP) is a cell-surface serine protease which promotes invasiveness of certain epithelial cancers and is therefore a potential target for cancer drug development and delivery. Unlike dipeptidyl peptidase IV (DPPIV), FAP exhibits prolyl endopeptidase activity and is active as a homodimer with specificity for type I collagen. The mechanism that regulates FAP homodimerization and its relation to prolyl endopeptidase activity is not completely understood. Here, we investigate key residues in the FAP TM domain that may be significant for FAP homodimerization. Mutations to predicted TM interfacial residues (G10L, S14L, and A18L) comprising a small-X3-small motif reduced FAP TM-CYTO dimerization relative to wild type as measured using the AraTM assay, whereas predicted off-interface residues showed no significant change from wild type. The results implied that the predicted small-X3-small dimer interface affect stabilization of FAP TM-CYTO homodimerization. Compared with FAPwild-type, the interfacial TM residue G10L significantly decreased FAP endopeptidase activity more than 25%, and also reduced cell-surface versus intracellular expression relative to other interfacial residues S14L and A18L. Thus, our results suggest FAP dimerization is important for both trafficking and protease activity, and is dependent on a specific TM interface.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibroblast activation protein; Homodimerization; Proteolytic activity; Transmembrane domain

Mesh:

Substances:

Year:  2016        PMID: 27155568     DOI: 10.1016/j.bbamem.2016.05.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic.

Authors:  Janessa Gerhart; Anastasia F Thévenin; Elizabeth Bloch; Kelly E King; Damien Thévenin
Journal:  ACS Chem Biol       Date:  2018-08-31       Impact factor: 5.100

Review 2.  The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes.

Authors:  Sara Hadjigol; Bansari A Shah; Neil M O'Brien-Simpson
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 3.  Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma.

Authors:  Hui-Ching Wang; Leong-Perng Chan; Shih-Feng Cho
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

4.  The prognostic significance of fibroblast activation protein-α in human lung adenocarcinoma.

Authors:  Jianlin Shi; Zongliu Hou; Jun Yan; Wanfang Qiu; Luxin Liang; Mingyao Meng; Lin Li; Xiaodan Wang; Yanhua Xie; Lihong Jiang; Wenju Wang
Journal:  Ann Transl Med       Date:  2020-03

5.  Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Authors:  W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs
Journal:  Immunotherapy       Date:  2020-11-05       Impact factor: 4.196

Review 6.  Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways.

Authors:  Go J Yoshida
Journal:  J Exp Clin Cancer Res       Date:  2020-06-16

Review 7.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.

Authors:  Ellen Puré; Rachel Blomberg
Journal:  Oncogene       Date:  2018-05-03       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.